COMMUNIQUÉS West-GlobeNewswire
-
Glass House Brands Announces the Filing of an Updated At-The-Market Distribution Program
15/07/2026 -
InnoCare Announces Phase III Study Results of TYK2 Inhibitor Soficitinib Meet Primary Endpoint in Patients with Atomic Dermatitis
15/07/2026 -
Ernexa Therapeutics Receives Independent Validation of ERNA-101 with Complete Tumor Clearance and Durable Survival in Ovarian Cancer Models Ahead of Planned Clinical Entry
15/07/2026 -
Profound Medical: Autonomous Robotics and Incisionless Surgery to Have Exceptional Presence at SRS2026
15/07/2026 -
Repligen to Report Second Quarter 2026 Financial Results
15/07/2026 -
Cellectar Biosciences Announces Publication of Phase 1 Study of Iopofosine I 131 in Peer-Reviewed Journal Cancers
15/07/2026 -
Acumen Pharmaceuticals Highlights Enhanced Brain Delivery™ (EBD™) Program Data and Early Alzheimer’s Disease Insights at the Alzheimer’s Association International Conference (AAIC®) 2026
15/07/2026 -
BriaCell Arranges Scalable Manufacturing with FUJIFILM Biotechnologies for Bria-IMT™
15/07/2026 -
The Coalition for Physician & APP Well-Being Launches “The Initiative Intelligence Guide” to Help Health Systems Better Evaluate Workforce, Retention, and Operational Initiatives
15/07/2026 -
Persephoni Backs SelSym Biotech to Bring Blood-Type-Agnostic Bleeding Control to the Point of Injury
15/07/2026 -
SciSparc: NeuroThera Labs Announces Initiation of Phase IIb Clinical Trial at Hannover Medical School in Germany for Innovative Treatment of Tourette Syndrome
15/07/2026 -
Sienna Announces July Dividend
15/07/2026 -
Alpha Tau Successfully Treats First Immunocompromised Patient with Recurrent Cutaneous Squamous Cell Carcinoma in its ADMIRE Study at Banner MD Anderson Cancer Center
15/07/2026 -
Nxera Pharma Webinar for Financial Results Presentation - 2Q2026
15/07/2026 -
Epoch Biotech Highlights New Preclinical Data for APOE Christchurch-Mimetic Antibody at AAIC 2026 Demonstrating Favorable PK/PD and Differentiated Biomarker Approach
15/07/2026 -
WONDERLAB Spotlights Gut Health and Innate Immunity, Featuring Its Proprietary Strain GOLDGUT-M520
15/07/2026 -
45,611 Orion Corporation A shares converted into B shares
15/07/2026 -
Boehringer Ingelheim reports first-half 2026 sales growth, driven by JARDIANCE® and new product launches in the U.S.
15/07/2026 -
FDA grants Priority Review to Roche’s Gazyva/Gazyvaro for adults with primary membranous nephropathy
15/07/2026
Pages